Superior Cancer Therapeutics. Found Faster.
Biology‑first AI for precision cancer therapeutics — unlocking intracellular pHLA targets.
- Proprietary pHLA datasets
- Integrated AI + wet‑lab validation for save therapeutics
- Pipeline in development
- Cancer affects 1 in 5 people worldwide. Our mission: accelerate the path to better therapeutics
Trusted & recognized by leading industry media
- WirtschaftsWoche
- Forbes
- Royal Society
of Chemistry - BioBiz Buzz
Validated pHLA data points
Proprietary datasets, growing weekly
Wet‑lab grounded
Every prediction tied to biology
WHERE DO YOU WANT TO START?
Choose your path — we'll meet you there.
MOST ASKED
FOR PHARMA & BIOTECH
Advance your pipeline with validated anti-pHLA therapeutics
De-risk antibody discovery with biology grounded AI and integrated wet-lab validation.
FOR INVESTORS
A scalable platform with real moats
Proprietary tech, data, and AI models, applied to a growing anti-pHLA pipeline.
FOR SCIENTISTS
Biology meets computation
Join a team turning high throughput data into actionable biology.
FOR PRESS & MEDIA
A new paradigm in drug discovery
Reframing how AI is applied to oncology — beyond prediction.
WHY BIOCOPY
Closing the gap between AI prediction and biological reality
BioCopy grounds AI prediction in experimental biology. Our platform integrates proprietary pHLA datasets, high-throughput validation, and continuous experimental feedback — so AI-driven predictions translate into functional biological outcomes from day one.
WHO WE ARE A research-driven biotech focused on safer anti-pHLA therapeutics.
BioCopy is building the next generation of anti-pHLA cancer biotherapeutics — backed by leaders in pharma, biotech, and antibody engineering. Our scientists, engineers, and drug developers are united by one goal: an AI-native discovery engine that changes how complex oncology programs are run.
WHAT WE DO Advancing pHLA-targeted drug discovery and programs.
BioCopy combines pHLA-targeted drug discovery, antibody engineering, and a growing portfolio of solid tumor programs. Our discovery engine — applied across internal and partnered projects — turns high-throughput experimental data into actionable signals for lead selection, candidate refinement, and development strategy.
HOW WE DO IT The BioCopy engine for AI-native pHLA discovery.
By combining AI-driven prediction and structural modeling with precision screening (ValidaTe®) and AI-ready data workflows, the BioCopy engine delivers earlier, safer calls on specificity, off-target risk, and candidate potential — from early discovery through lead optimization.
Platform
A fully integrated discovery platform
Four connected stages that turn biology into validated therapeutic candidates — reducing risk, increasing hit rates, and accelerating iteration as a natural by-product.
Lead Therapeutics
Identify biologically active, de-risked anti-pHLA therapeutics with greater precision and confidence.
ValidaTe: Precision screening at scale
Detect off-target binding risks and specificity issues early — before they become costly failures. Thousands of interactions profiled in a single run, giving teams a complete view of the candidate profiles.
PIPELINE
From platform to pipeline
BioCopy is advancing a growing pipeline of pHLA targeted programs — demonstrating the scalability and translational power of its platform.
DATA & AI
Biology grounded intelligence
Our models are powered by proprietary biological datasets — ensuring predictions are rooted in real world biology, not synthetic abstractions.
This approach enables more reliable lead identification and a higher probability of success.
Proprietary datasets
Experimental data generated in house — structured, consistent, and continuously growing.
Models rooted in biology
Predictions are anchored in real world biology, validated through experimental feedback.
PARTNERSHIPS
Built for collaboration —
de-risk your next pHLA program.
We partner with biopharma teams to accelerate discovery and development of precision therapeutics — integrating seamlessly into your existing pipelines.
Validated anti-pHLA therapeutics — not just predictions
Every candidate is grounded in proprietary wet lab data, reducing late stage attrition.
Plugs into your R&D, not the other way around
Modular engagement: target credentialing, antibody lead discovery, antibody lead optimization, or full programs.
Faster, better-informed decisions
Specificity and off target signals delivered in weeks, not months.
NDA on request · No obligation
Build the future of precision therapeutics
Join a team working at the intersection of biology and computation — where your research directly shapes real world therapies.
Redefining AI in drug discovery
Perspectives, publications, and company news on closing the gap between AI prediction and biological reality.
Get in touch
Let’s redefine drug discovery —
together.
Whether you want to partner, invest, join, or simply learn more — tell us what you’re working on. We’ll route you to the right person.
- Validated anti-pHLA therapeutics — not just predictions
- Confidential by default · NDA on request
- No sales calls — only direct conversations with our team
Send us a message
By submitting, you agree to our privacy policy. We'll never share your data.